Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an appalling prognosis. The failure of anti-inflammatory therapies coupled with the observation that deranged epithelium overlies proliferative myofibroblasts to form the fibroblastic focus has lead to the emerging concept that IPF is a disease of deregulated epithelialmesenchymal crosstalk. IPF is triggered by an as yet unidentified alveolar injury that leads to activation of transforming growth factor-b (TGF-b) and alveolar basement membrane disruption. In the presence of persisting injurious pathways, or disrupted repair pathways, activated TGF-b can lead to enhanced epithelial apoptosis and epithelial-to-mesenchymal transition (EMT) as well as fibroblast, and fibrocyte, transformation into myofibroblasts which are resistant to apoptosis. The resulting deposition of excess disrupted matrix by these myofibroblasts leads to the development of IPF.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease. The prognosis of people with IPF is similar to that of stage 1 and 2 non-small cell lung cancer with a median survival, from diagnosis, of less than 3 years and people die on average 7 years prematurely [Raghu et al. 2006a; Hubbard et al. 1998 ]. The clinical presentation of IPF is characterized by progressive breathlessness on exertion and a dry irritating cough. The presence of digital clubbing and crackles are commonly found on examination, and a diagnosis is confirmed by the characteristic features of basal, subpleural honeycombing on high-resolution computerized tomography (HRCT) scanning. The pathological hallmark of IPF is the presence of usual interstitial pneumonia (UIP) on biopsy. The key features of UIP include the presence of hyperplastic reparative epithelium overlying aggregates of myofibroblasts giving rise to the so-called 'fibroblastic focus' [Katzenstein and Myers, 1998 ]. These lesions are patchy and temporally heterogeneous, with inflammation being conspicuous by its absence [Harari and Caminati, 2010] . The combination of these relatively quiescent biopsy findings and the failure of conventional anti-inflammatory strategies to alter the clinical course of IPF has lead to a shift from considering fibrosis as an inflammatory lung disease to a disease of impaired epithelial injury and repair.
The pathogenesis of IPF is incompletely understood and hypotheses continue to evolve. There is still no unifying mechanism that can explain all lung fibrogenesis, and it is likely that a multitude of factors play a role. The current paradigm suggests that following repeated subclinical injury to the lung there is epithelial damage with subsequent destruction of the alveolarcapillary basement membrane. This permits fibrogenic cell infiltration of the alveolar interstitium, with activation of fibroblasts leading to the generation of the highly contractile, synthetic alpha-smooth muscle actin positive (aSMA) myofibroblast considered to be the key effector cell in pulmonary fibrosis [Eickelberg and Laurent, 2010; Strieter and Mehrad, 2009] . At what point failure of epithelial repair following injury leads to the deposition of disordered collagen exceeding collagen degradation and subsequent lung fibrosis is not known. However, factors that promote epithelial injury, through persisting inflammation, or inhibit epithelial repair, through reduced epithelial proliferation and increased apoptosis, promote fibrosis. Likewise, processes that promote matrix deposition through enhanced myofibroblast transformation and proliferation along with retarded apoptosis are also fibrogenic. These observations, have given rise to the concept that IPF is a disease of disordered epithelialmesenchymal crosstalk.
The causal insult in IPF is, by definition, unknown. The current hypothesis of the pathogenesis of IPF suggests that it is a disease of persisting lung injury and ineffective wound repair. Under normal circumstances alveolar injury leads to epithelial and endothelial injury, vascular leak and oedema, with inflammatory cell recruitment. This is followed by provisional matrix deposition. This inflammatory phase of injury and repair resolves via apoptosis and phagocytosis of inflammatory and mesenchymal cells with restoration of normal, functional pulmonary architecture. However, in IPF these processes become dysregulated either through persisting injury or aberrant repair. In related conditions where the aetiology is known, fibrosis appears to be driven by persisting injury that is either mediated via immune complexes, in hypersensitivity pneumonitis, inhaled agents including asbestos, or directly toxic agents such radiation or chemicals. It is, therefore, possible that persisting injury or inflammation as well as failed repair promote fibrosis in IPF.
Inflammation
The role of inflammation in the pathogenesis of IPF is controversial. This is in part due to the relative paucity of inflammatory cells in the fibroblastic focus, the pathological hallmark of IPF, and in part due to failure of anti-inflammatory strategies in treating IPF. However, the concept of inflammation is itself an evolving process as we improve our understanding of the contribution of different inflammatory cell types to both tissue destruction and repair. Furthermore, the nature of the host inflammatory response is determined by the nature of the initiating insult, the origin of which remains elusive in IPF. Thus, it is possible that inflammatory signals are too subtle to be picked up on a routing histological assessment of a surgical lung biopsy, likewise it is conceivable that anti-inflammatory strategies impair both the detrimental and beneficial aspects of an inflammatory response rendering them ineffective. Furthermore, a lack of understanding of the initiating injury and consequent inflammatory response hinders appropriate targeting of inflammatory cells or mediators. In fibrogenesis the inflammatory response can be broadly divided into pathways that promote fibrosis, and pathways that inhibit fibrosis. The historical concept that lung fibrosis is the inevitable consequence of an unchecked 'alveolitis' is incorrect and for inflammation to lead to fibrosis there must also be some failure of wound repair, which could result from an imbalance in these inflammatory pathways.
Neutrophils
Neutrophil infiltration is characteristic of acute lung injury responses. Neutrophils are a source of matrix degrading enzymes including neutrophil elastase, and high levels of this enzyme have been found in lung parenchyma of patients with IPF [Obayashi et al. 1997 ]. Furthermore, inhibiting neutrophil elastase function, through targeted deletion of the gene in ne À/À mice or using a specific inhibitor of NE, leads to reduced fibrosis in experimental models of disease [Chua et al. 2007; Taooka et al. 1997 ]. However, deleting neutrophils completely can increase levels of lung collagen, at least in the early stages of lung injury [Clark and Kuhn, 1982; Thrall et al. 1981] demonstrating the complexity of these pathways in fibrogenesis. In patients with IPF elevated levels of interleukin (IL)-8, an important neutrophil chemoattractant, correlate with lung function impairment and prognosis Hiwatari et al. 1991 ]. Furthermore, neutrophilic inflammation superimposed on IPF leads to a worsening of the prognosis [Ziegenhagen et al. 1998; Gilligan et al. 1990; Watters et al. 1987; Rudd et al. 1981] and acute exacerbations of IPF, a common and severe complication of fibrosis, are characterized by diffuse alveolar damage and a marked neutrophil influx [Tiitto et al. 2006; Parambil et al. 2005; Ambrosini et al. 2003 ]. The mechanism by which neutrophils promote fibrosis is unclear, Therapeutic Advances in Respiratory Disease 4 (6) however data from ne À/À mice suggests that it could be via elastase-mediated activation of TGF-b [Chua et al. 2007 ].
Lymphocytes
Initial work in experimental models suggested that lymphocytes promoted fibrosis [Piguet et al. 1993; Schrier et al. 1983] , although lymphocytosis in patient samples is often associated with milder disease [Fireman et al. 1998; Watters et al. 1987; Rudd et al. 1981] . It is now clear that lymphocyte subsets have differing roles in fibrogenesis with Th2 lymphocytes being profibrotic [Wynn, 2008] . IL-4 is the archetypal Th2 cytokine and levels are increased in patients with IPF resulting in elevated collagen production from fibroblasts [Wallace et al. 1995; Sempowski et al. 1994; Emura et al. 1990 ]. IL-4 is also able to promote alternative activation of macrophages [Martinez-Pomares et al. 2003 ], IL-5 and IL-13 secretion as well as TGF-b activation from eosinophils and mast cells [Wilson and Wynn, 2009] . A recent study assessing CD4 þ CD28 null lymphocytes, as a marker of chronic adaptive immune responses, demonstrated reducing levels of CD28 expression in patients with severe disease. These cells also produced higher levels of IL-4 and lower levels of IL-10 than CD4 þ CD28 þ lymphocytes [Gilani et al. 2010] . Similarly IL-13, another Th2 cytokine, is potently pro-fibrotic leading to fibroblast transformation to myofibroblasts [Ingram et al. 2004] . Studies in animal models have illustrated that inhibiting IL-13 function ameliorates lung fibrosis [Jakubzick et al. 2003; Kolodsick et al. 2003; Belperio et al. 2002] , whereas overexpression of IL-13 promotes fibrosis Zhu et al. 1999] . Interestingly mice that are null for the IL-4 gene are still able to develop fibrosis [Kolodsick et al. 2004 ]. This suggests some compensation between the IL-4 and IL-13 pathways, which is unsurprising given the shared receptors used by these cytokines. More recently the Th17 cytokine IL17A has been shown to promote fibrosis via a TGF-b1-dependent mechanism [Wilson et al. 2010] . Thus, lymphocytes via Th2 and Th17 responses can promote fibrosis, however other lymphocyte functions may aid repair. Regulatory T cells (Treg) cells are primarily involved in attenuating inflammatory responses following injury. These cells are characterized by the presence of CD25 on the cell surface and intracellular FoxP3. CD4 þ CD25 þ FoxP3 þ cells are reduced both numerically and functionally in patients with IPF [Kotsianidis et al. 2009 ]. Furthermore, a key Treg product IL-10 has anti-inflammatory, and possible antifibrotic effects. IL-10 gene delivery can inhibit bleomycin-induced lung fibrosis and this may also be via inhibiting effects on TGF-b [Nakagome et al. 2006; Arai et al. 2000 ], although it may simply be via reducing levels of tissue injury through dampening of the inflammatory response [Haase et al. 2007] .
Monocytes
Not only are neutrophils, and their chemotactants, elevated in IPF, but monocytes and monocyte chemotactant protein 1 (CCL2) and macrophage colony stimulating factor 1 are also increased in the bronchoalveolar lavage (BAL) of patients with IPF [Baran et al. 2007; Car et al. 1994] . The elevated levels of CCL2 are due to increased synthesis by fibrotic epithelial cells [Antoniades et al. 1992] , which may be in response to local coagulation acting through the protease-activated receptor 1 (PAR1) ]. Studies inhibiting the function of CCL2 either through blocking antibodies or gene deleted mice demonstrate protection from fibrosis in these models suggesting that CCL2 is a profibrotic molecule [Inoshima et al. 2004; Moore et al. 2001 ]. Furthermore, it is possible that CCL2 has profibrotic consequences unrelated to its monocyte chemotactant properties via effects on CCR2 expression on T cells [Deshmane et al. 2009 ].
Pulmonary monocytes have traditionally been considered profibrotic, through release of profibrotic mediators such as PDGF [Martinet et al. 1987 ], but it is now becoming clear that both alveolar macrophages and pulmonary dendritic cells may be vital for wound repair following inflammatory responses. It has been demonstrated that alveolar macrophages [Atabai et al. 2009] , and pulmonary dendritic cells, limit the development of pulmonary fibrosis [Manicone et al. 2009 ].
Profibrotic chemokines and angiogenesis
Several chemokines including those involved in angiogenesis have been implicated in the pathogenesis of IPF. However, the role of angiogenesis in IPF is, like inflammation, controversial. Angiogenesis, defined as the process of new blood vessel growth, is an important component of wound healing and some authors believe it may contribute to the fibroproliferative and extracellular matrix deposition observed in IPF [Magro et al. 2003; Peao et al. 1994] . In contrast, several reports that question the role of angiogenesis in fibrosis describe decreased neovascularization in fibroblastic foci of patients with IPF with increased levels of potent angiostatic factors [Renzoni et al. 2003 ]. Pulmonary systemic vascular anastamoses have been demonstrated in patients with IPF [Turner-Warwick, 1963] , and these correlate with increased levels of the pro-angiogenic chemokines CXCL8, CXCL5, CXCL2 [Simler et al. 2004 ] and decreased expression of the angiostatic chemokine CXCL10 [Keane et al. 1997 ] with epigenetic repression playing a role in the decreased expression in IPF [Coward et al. 2010 ]. Inhibition of angiogenic chemokines and administration of angiostatic chemokines in a murine model of fibrosis have been shown to attenuate the induced pulmonary fibrosis [Burdick et al. 2005; Keane et al. 2001 Keane et al. , 1999 . Mice deficient in the angiostatic chemokine CXCL10 develop increase pulmonary fibrosis following bleomycin-induced lung injury [Tager et al. 2004 ]. Thus, it is possible that an imbalance between angiogenic and angiostatic factors favours the development of IPF.
Antifibrotic inflammatory responses
During persistent lung injury it is thought that a failure to respond with a robust Th1 response promotes the development of IPF [Strieter and Keane, 2004] . Interferon-g (IFN-g) is the pivotal Th1 cytokine and there are low levels of IFN-g synthesis by lymphocytes from the patients with IPF. IFN-g inhibits fibroblast proliferation and collagen synthesis [Narayanan et al. 1992; Clark et al. 1989 ]. Recombinant IFN-g prevents collagen deposition in the lungs of bleomycin-treated rodents with corresponding reductions in TGF-b mRNA [Gurujeyalakshmi and Giri, 1995; Okada et al. 1993] , as well as downregulating fibroblastinduced TGF-b signalling [Eickelberg et al. 2001 ]. Furthermore, inhibiting IFN responses either through deletion of the CXCR3 receptor, which mediates increased IFN in response to IFN-g inducible chemokines, or using an anti-IFN-g monoclonal antibody inhibits the development of experimental fibrosis [Jiang et al. 2004 ]. However, despite the antifibrotic effects of IFN-g use of recombinant IFN-g does not improve the outcome of patients with IPF [King et al. 2009 ], suggesting either that augmenting IFN is not sufficient to repolarize Th1/Th2 responses or that it is occurring too late to alter the course of established fibrosis.
It is clear that inflammation may have a crucial role to play in the development of IPF.
Exaggerated inflammatory responses can lead to excessive injury which overwhelm repair processes, immune switching to Th2 rather than Th1 responses may further promote fibrosis, whereas impaired resolution through reduced monocyte MFGE8 or matrilysin, or reduced Treg and IL10 synthesis, may limit repair in response to an otherwise trivial injury. However, for lung fibrosis to occur there must be failure of epithelial repair with matrix deposition in its place.
Epithelial repair
Alveolar epithelial repair IPF is a disease affecting the alveolar interstitium. The alveolus is composed of alveolar type 1 and 2 epithelial cells that adhere to the alveolarcapillary basement membrane. This delicate structure may be damaged by environmental exposure to various dusts [Taskar and Coultas, 2006; Hubbard et al. 1996] , gastrooesophageal reflux [Raghu et al. 2006b ] and viral infections [Kelly et al. 2002; Stewart et al. 1999] , all of which have been hypothesized to promote pulmonary fibrosis. Following injury, normal wound healing requires that an intact epithelium is restored swiftly to prevent excess mesenchymal activation. This requires coordinated, spatially and temporally regulated responses, including inflammatory responses and activation of local coagulation pathways, the formation of a provisional matrix along which activated myofibroblasts migrate promoting wound contraction. Epithelial cells migrate over basal layers to regenerate the damaged area of lung, before cellular debris and provisional matrix are remodelled and removed. In IPF the epithelium is markedly abnormal showing evidence of hyperplastic type 2 alveolar (ATII) cells, transitional epithelial cells with areas of bronchiolization and squamous metaplasia. The integrity of the basement membrane remains disrupted with hyperplastic ATII cell proliferation on an inappropriate extracellular matrix without restoration of normal alveolar structures [Basset et al. 1986 ]. Furthermore, in lung fibrosis there is upregulation of epithelialassociated molecules involved in repair and development including integrins and components of the WNT signalling pathway [Konigshoff and Eickelberg, 2010; Margadant and Sonnenberg, 2010] and recently, it has been shown that specific ATII cell injury is sufficient to promote pulmonary fibrosis in a model of targeted type II cell injury [Sisson et al. 2010 ]. Thus, it is likely that fibrosis occurs in a setting of ineffective epithelial repair. A key process in epithelial injury and repair is the activation of epithelial TGF-b.
Epithelial activation of TGF-TGF-b is a member of the TGF-b superfamily, a highly conserved group of cytokines of which there are three mammalian isoforms (TGF-b1, -b2 and -b3). The effects of TGF-b1 have been best characterized in pulmonary fibrosis, and from this point references to TGF-b will relate to TGF-b1 unless specified otherwise. TGF-b is a pleiotropic cytokine that is ubiquitously expressed by all cells and tissues within the body. TGF-b has profound effects on epithelial cells and fibroblasts, which are central to the pathogenesis of pulmonary fibrosis. TGF-b promotes epithelial cell apoptosis [Hagimoto et al. 2002] , epithelial-to-mesenchymal transition (EMT) [Kim et al. 2006 ], epithelial cell migration [Yu et al. 2008] , collagen synthesis, fibroblast proliferation and transformation into myofibroblasts [Scotton and Chambers, 2007] . TGF-b also induces a pro-angiogenic environment, via the induction of key angiogenic factors including connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF) in both epithelial cells and fibroblasts [Sánchez-Elsner et al. 2001 ]. TGF-b can also induce the expression, secretion and activation of matrix metalloproteinase 2 (MMP2) and MMP9, and the downregulation of tissue inhibitor of metalloproteinase (TIMP) [Derynck et al. 2001] , processes that are both implicated in IPF. Furthermore, the role of TGF-b is well described in IPF. TGF-b is increased in tissue samples from both animal models of IPF [Coker et al. 1997 ] and IPF patients [Coker et al. 2001 ]. Overexpression of an adenovirus encoding active TGF-b leads to persistent pulmonary fibrosis [Sime et al. 1997] and inhibiting TGF-b with soluble TGF-b receptor , or a TGF-b receptor 1 (ALK5) inhibitor [Bonniaud et al. 2005] ameliorates pulmonary fibrosis. Furthermore, mice null for the TGF-b signalling molecule Smad3 are protected from pulmonary fibrosis [Zhao et al. 2002] .
TGF-b is synthesized as a small latent complex consisting of active TGF-b noncovalently associated with the latency-associated peptide (LAP), which in turn is secreted by most cells in association with the latent TGF-b binding proteins (LTBPs) as the large latent complex. The large latent complex is sequestered as an inactive molecule that is stored in the extracellular matrix. For TGF-b to exert biological effects it must be activated, by dissociating from, or altering its interaction with, LAP. Several processes can cause this, including physical processes such as temperature extremes, low pH and oxidation. TGF-b can also be activated by a number of proteases, including plasmin, tryptase, thrombin, elastase, MMP-2 and MMP-9 [Tatler et al. 2008; Karsdal et al. 2002; Yu and Stamenkovic, 2000; Taipale et al. 1992 ]. However, the importance of these mechanisms in vivo has yet to be defined. The best-characterized mechanisms of in vivo TGF-b activation are mediated by interactions with thrombospondin or integrins, and in pulmonary fibrosis the bestcharacterized mechanism of TGF-b activation is by the avb6 integrin.
v6 integrin-mediated TGF-activation Integrins are heterodimeric transmembrane proteins consisting of a and b subunits. They are capable of binding to extracellular matrix proteins as well as a range of other molecules, including cell surface ligands, transmembrane proteins, soluble proteases and growth factors [Humphries et al. 2006 ]. The mammalian genome encodes 26 integrins, comprising 18 a subunits and 8 b subunits that heterodimerize to form 24 ab combinations. Eight integrins, including all five av-containing integrins, bind ligands through an arginineglycineaspartate (RGD) sequence. An RGD sequence is found in the LAP of TGF-b1 and TGF-b3, which facilitates the activation of TGF-b by at least four avcontaining integrins (avb3, avb5, avb6 and avb8) in vitro. The LAP of TGF-b2 does not contain an RGD motif and no integrin-mediated activation of TGF-b2 has been described.
The avb6 integrin was the first integrin to be implicated in the activation of TGF-b [Munger et al. 1999 ]. Expression of the avb6 integrin is significantly increased in injured epithelia, but overexpression is not sufficient to promote fibrosis [Huang et al. 1998 ]. The avb6 integrin itself must be activated before TGF-b activation can occur, and the evidence suggests that this occurs in response to cytoskeletal changes. The cytoplasmic tail of the b6 subunit binds to the actin cytoskeleton, and mutation of this domain, or treatment of cells with cytochalasin D, an inhibitor of actin polymerization, abolishes avb6 integrin-mediated TGF-b activation [Munger et al. 1999] . In addition, in cells lacking LTBP-1, avb6 cannot activate TGF-b, therefore, avb6-integrinmediated TGF-b activation is critically dependent on the association of latent TGF-b with LTBP-1 [Annes et al. 2004 ]. TGF-b-activating activity can be restored by inducing the expression of a short fusion protein with regions mimicking the LAP-binding and extracellular-matrix-binding domains of LTBP-1 [Annes et al. 2004] . Overall, these studies suggest that avb6-mediated TGF-b activation is dependent upon tethering of the avb6-integrin-TGF-b complex to the cell surface.
The avb6 integrin is constitutively bound to TGF-b suggesting that the system is primed to detect injurious stimuli. A pathway through which injurious signals are transmitted to the avb6 integrin was described recently [Jenkins et al. 2006 ]. Thrombin and lysophosphatidic acid (LPA) are G-protein-coupled receptor agonists, and both of these substances have been shown to promote avb6-integrin-mediated TGF-b activation and are implicated in the development of IPF [Tager et al. 2008; Howell et al. 2002] . Thrombin and LPA activate avb6integrin-mediated TGF-b activation via the protease-activated receptor-1 (PAR1), and lysophosphatidic acid receptor 2 (LPAR2) respectively, which in turn induce cytoskeletal changes via the G-protein Ga q , RhoA and Rho kinase ]. Therefore, inflammatory mediators released in response to tissue injury activate TGF-b, by binding to epithelial cell surface receptors and inducing cytoskeletal contraction, resulting in a conformational change in the avb6 integrin-latent TGF-b complex.
The v6 integrin and IPF
In vivo data has demonstrated the importance of avb6-integrin-mediated TGF-b activation in the pathogenesis of IPF. Mice that do not express the b6 subunit (itgb6 À/À mice) cannot form the avb6 integrin. These mice develop mild inflammation in the lungs and skin, but are protected from bleomycin-, LPS-and ventilator-associated lung injury, as well as bleomycin-induced pulmonary fibrosis and renal fibrosis [Jenkins et al. 2006; Ma et al. 2003; Munger et al. 1999 ]. In addition, an anti-avb6 monoclonal antibody has been shown to prevent pulmonary fibrosis, renal fibrosis, and acute lung injury in vivo [Puthawala et al. 2008; Munger et al. 1999 ].
Expression of the b6 subunit gene (itgb6) is increased at the message level in bleomycininduced lung fibrosis ] and at the protein level in IPF patients Horan et al. 2008 ]. This suggests that although increased avb6 integrin expression is insufficient to increase TGF-b activation, abnormal regulation of the avb6 subunit may participate in the pathogenesis of IPF. Indeed TGF-b itself upregulates itgb6 expression [Wang et al. 1996] , possibly mediated via the ets1 transcription factor [Bates et al. 2005 ]. This process can be inhibited by blocking TGF-b, or the avb6 integrin, suggesting a self-amplifying paracrine loop [Araya et al. 2007 ]. Thus, lung injury promotes avb6-integrin-mediated TGF-b activation, which, in turn, induces a feed-forward, selfamplifying loop, through increased itgb6 gene expression. A key feature of avb6 integrin mediated TGF-b activation is the absolute requirement for cellcell contact between cells expressing the integrin and the TGF-b receptor [Munger et al. 1999 ]. Thus, it is likely that the destruction of the epithelial basement membrane is a key step in promoting fibrogenesis by this pathway, because the persisting disruption of the epithelial basement membrane permits the interaction of the fibrogenic effector cells with the damaged epithelial cells (Figure 1 ).
Epithelial-related coagulopathy
Experimental data, both in vitro and in vivo, have demonstrated the importance of the clotting cascade in fibrogenesis, and fibrin deposition is a feature of both IPF and experimental models of fibrosis [Chambers, 2003] .
The serine protease plasmin cleaves fibrin, promoting matrix breakdown. Strategies that inhibit plasmin activity exacerbate bleomycininduced pulmonary fibrosis [Eitzman et al. 1996] , whereas augmenting plasmin activity ameliorates fibrosis [Sisson et al. 2002; Hattori et al. 1999; Kotani et al. 1995] . Furthermore, acute lung injury and pulmonary fibrosis are characterized by increased fibrin deposition and impaired fibrinolysis [Fujii et al. 2000; Imokawa et al. 1997; Kotani et al. 1995; Bertozzi et al. 1990; Chapman et al. 1986 ]. The reduced fibrinolytic activity may be because of high levels of plasminogen activator inhibitor 1 (PAI-1) found in patients with ALI and IPF [Kotani et al. 1995; Bertozzi et al. 1990 ]. Epithelial PAI-1 is synthesized predominantly following TGF-b activation and can be used as a marker of TGF-b activity ]. Thus, epithelial injury may, through TGF-b activation and PAI-1 synthesis, act to inhibit plasmin activity, which in turn Therapeutic Advances in Respiratory Disease 4 (6) promotes fibrosis through reduced fibrinolysis. Similarly epithelial injury promotes the synthesis of activated factor X, which in turn activates TGF-b, via the signalling receptor PAR1 on fibroblasts, promoting myofibroblast differentiation ]. Other coagulation proteins have been implicated in fibrotic lung disease in both human studies and animal models Howell et al. 2005 Howell et al. , 2001 Hernandez-Rodriguez et al. 1995] . Thrombin not only promotes fibrin deposition through cleavage of fibrinogen, but, furthermore, induces avb6-integrin-mediated TGF-b activation via epithelial PAR1, leading to subsequent fibrosis [Jenkins et al. 2006 ].
The importance of these pathways in IPF is demonstrated by studies that have inhibited coagulation with hirudin, nebulized heparin, urokinase or activated protein C, all of which have been shown to ameliorate experimental lung fibrosis [Gunther et al. 2003; Howell et al. 2001; Yasui et al. 2001 ]. Furthermore, one clinical trial has been performed showing that patients treated with warfarin, or heparin, had improved survival compared with patients who were not anticoagulated. This raises the possibility that anticoagulation might be useful in treating patients with IPF [Kubo et al. 2005] .
The origin of myofibroblasts

Introduction
Although epithelial injury is probably the precipitating factor for fibrosis to occur, the underlying interstitial cells need to respond in a way that prevents wound healing, and promotes fibrogenesis in order for pathological disease to occur.
The key mesenchymal features of pathological fibrosis are increased numbers of transdifferentiated fibroblasts that become more contractile in their phenotype, due to enhanced aSMA expression and are known as myofibroblasts [Scotton and Chambers, 2007] . These cells share features with both fibroblasts and smooth muscle cells and are probably responsible for the enhanced synthesis of abnormal matrix observed in pulmonary fibrosis. Myofibroblasts are also important cells in the stoma of neoplasms, and are often found at the leading edge of invasive tumours [Vancheri et al. 2010 ]. The recent finding that the fibroblastic focus is not an isolated lesion, rather a complex interconnected reticulum of polyclonal mesenchymal proliferation [Cool et al. 2006 ], has lead some to consider that IPF may be a malignant mesenchymal disease [Vancheri et al. 2010] and its prognosis would certainly support this view. Recently, attention has focused on the origin of the myofibroblast, as it is clear that the accumulation of these cells is a central feature in the pathology of IPF.
Activation of resident fibroblasts
The most well-established, and straightforward, explanation for the increase in myofibroblasts is that quiescent resident interstitial fibroblasts proliferate and transdifferentiate into activated myofibroblasts in response to growth factors including TGF-b, PDGF and CTGF. PDGF is a potent mitogen for fibroblasts and myofibroblasts [Bonner, 2004] and similarly CTGF, which acts in concert with a number of profibrotic mediators, can promote fibroblast differentiation and matrix synthesis [Leask and Abraham, 2003] . As described earlier TGF-b is activated by epithelial injury and is mitogenic for fibroblasts, as well as being the most potent inducer of extracellular matrix generation described to date [Scotton and Chambers, 2007] . More recently an intriguing hypothesis has emerged suggesting that it may in fact be the matrix itself that promotes the differentiation of fibroblasts into myofibroblasts. Fibroblasts form only loose attachment to the matrix, but as the matrix stiffens during wound repair the phenotype of the fibroblast changes to that of a myofibroblast [Hinz, 2010] . It is possible that this phenotypic change in response to increased matrix stiffness is through activation of TGF-b.
It is likely that matrix stiffness is crucial for appropriate tension to be exerted through the cytoplasmic domain of integrins that activate TGF-b. Myofibroblasts do not express the avb6 integrin but cellular traction has also been proposed to induce TGF-b activation via avb3 and avb5 [Wipff et al. 2007 ]. Blocking avb5 function inhibits contraction-mediated TGF-b activation, which also occurs to a lesser extent with b1 and avb3 [Wipff et al. 2007] , and this integrin-mediated TGF-b activation is limited to culture substrates with stiffness comparable to fibrotic tissue, suggesting that this mechanism maintains TGF-b activation after fibrosis has begun. Both the avb3 and the avb5 integrins are upregulated in the dermal epithelium in systemic sclerosis, and can activate TGF-b in scleroderma fibroblasts promoting transformation into myofibroblasts [Asano et al. 2006 [Asano et al. , 2005 .
Epithelial-to-mesenchymal transition
Under certain circumstances when epithelial cells become detached from their basement membrane, they migrate and downregulate epithelial cell markers whilst simultaneously upregulating mesenchymal markers [Moustakas and Heldin, 2007; Thiery and Sleeman, 2006 ]. This process is termed EMT and is a central and welldescribed process in embryogenesis and may play a role in the pathogenesis of IPF . Injury has been recognized to promote EMT leading to fibrosis in a number of organs including the eye [Saika et al. 2004] , kidney [Iwano et al. 2002] and liver [Zeisberg et al. 2007 ]. Within the lung, primary rat epithelial cells have been shown to undergo EMT in response to TGF-b or endothelin-1 [Jain et al. 2007; Yao et al. 2004] , similarly primary human cells also undergo EMT in response to TGF-b which appears to be avb6 integrin dependent [Kim et al. 2006 ]. There is direct evidence that EMT can occur in vivo using lineage tracing in murine models of lung fibrosis which have lead to estimates that up to 30% of fibroblasts may be of epithelial origin [Tanjore et al. 2009; Kim et al. 2006] . Similarly in sections of lung tissue taken from patients with IPF there is evidence of colocalization of both epithelial and mesenchymal markers suggesting cells that are undergoing EMT [Pozharskaya et al. 2009 
Fibrocytes
The third potential origin of myofibroblasts during the development of IPF is from circulating fibroblast precursor cells, or fibrocytes. These cells were first identified as circulating cells that Therapeutic Advances in Respiratory Disease 4 (6) migrated into wounds facilitating repair [Bucala et al. 1994] . They are believed to be bone-marrow-derived cells and express both haematological and stromal markers (CD45, CD34, Collagen 1, 3 and fibronectin) [Strieter and Mehrad, 2009 ]. Similar to resident cells, including fibroblasts and epithelial cells, they respond to TGF-b, and also endothelin, by transdifferentiating into myofibroblasts [Hong et al. 2007; Schmidt et al. 2003 ]. Murine models have shown that between 20% and 50% of fibroblasts originate from the bone marrow [Tanjore et al. 2009; Hashimoto et al. 2004] , and inhibiting trafficking and extravasation of fibrocytes into the lung ameliorates pulmonary fibrosis ]. There is also evidence that fibrocytes contribute to the fibrosis observed in patients with IPF, with higher levels of fibrocytes being identified in the peripheral blood of patients with IPF [Andersson-Sjoland et al. 2008 ]. More recently, data have suggested that high levels of circulating fibrocytes may reflect disease activity and could be used as a marker of early mortality in patients with IPF [Moeller et al. 2009 ]. Regardless of the origin of the myofibroblasts, the molecular checkpoint that determines the fate the myofibroblast precursor cells has not yet been determined but may be due to alterations in the regulation of gene expression.
Epithelialmesenchymal crosstalk
Introduction
The current paradigm suggests that inflammatory responses contribute to epithelial injury that, in turn, promotes matrix deposition from matrix synthesizing cells. In normal homeostatic responses the crosstalk between the cellular components of the wound repair process leads to reconstitution of the original tissue. It is likely that signalling pathways that are involved in these processes become disrupted leading to the aberrant crosstalk and failing repair. Although inflammatory pathways may be responsible for failed repair and were discussed earlier, it is currently considered more likely that abnormal epithelialmesenchymal crosstalk leads to excessive matrix deposition following simple injury. There are two key pathways involved in epithelialmesenchymal crosstalk. Epithelial activation of TGFb leading to mesenchymal responses has been discussed above. A further key pathway, especially in EMT-dependent processes, is the WNT signalling pathway.
WNT signalling
WNTs are secreted glycoproteins, which are highly conserved across species and are essential for many physiological and developmental processes. There are currently 19 WNT proteins identified in humans, and at least 10 mammalian Frizzled (Fz) receptors and their coreceptors lowdensity lipoprotein related receptor (LRP) 5/6, plus ROR and Ryk receptor families that can bind the WNT proteins [Schlessinger et al. 2010] . This leads to considerable complexity in WNT signalling, which can be divided into at least three recognized, distinct signalling pathways.
The canonical WNT signalling pathway is, under basal conditions, a 'destruction complex'. In the absence of WNT ligands, glycogen synthase kinase-3b (GSK-3b) and casein kinase 1a (CK1a) phosphorylate b-catenin on the axin/ adenomatous polyposis coli (APC) scaffold complex. This phosphorylated b-catenin is degraded following ubiquinitation leading to low basal levels of b-catenin [Liu et al. 2002; Kitagawa et al. 1999; Ikeda et al. 1998 ]. Upon ligation of the WNT receptor Fz and its coreceptor LRP5/6, the destruction complex is inactivated, and b-catenin accumulates, and translocates to the nucleus and, with coactivators T-cell factor (TCF) and lymphoid enhancer factor (LEF), leads to transcriptional upregulation of various genes [Kikuchi et al. 2007 ].
Less well understood are the noncanonical pathways including the WNT/Ca 2þ signalling pathway which acts via calmodulin kinase II and protein kinase C and possibly Cdc42, and the planar cell polarity (PCP) pathway. This latter pathway promotes polarization and involves asymmetric segregation of proteins permitting spatial coordination of cell growth and development. This pathway shares the Fz downstream mediator Dishevelled with the canonical pathway, but leads to activation of the small GTPases Rac and Rho through unknown mechanisms but may involve spatial regulation of the Fz/Dishevelled complex [Schlessinger et al. 2010] . Many WNT ligands appear to activate both canonical and noncanonical pathways, whereas some, such as WNT5a, appear to be pathway specific [Konigshoff and Eickelberg, 2010] .
WNT signalling in IPF WNT signalling is crucial for the development of many organs including the lung and aberrant signalling of this pathway is well described in many tumours, most notably colon cancer [Morrisey, 2003] , but also hepatocellular and non-small cell lung cancer [Konigshoff and Eickelberg, 2010; Nusse, 2005] . More recently data have emerged suggesting that this pathway may be important in fibrogenesis.
Studies analysing gene arrays have revealed overexpression of WNT2, WNT5a and Fz7 and Fz10 and WNT regulators sRP1 and sRP2, as well as downstream mediators including WNT1-inducible signalling protein (WISP1) in IPF lungs compared with controls [Selman et al. , 2006 Yang et al. 2007 ]. Furthermore, nuclear localization of b-catenin is found in the fibroblastic foci of patients with IPF but not diseases such as NSIP or DAD [Chilosi et al. 2003 ]. Evidence of functional activation of this pathway has been described in both fibroblasts and epithelial cells in experimental models and patient samples. WNT ligands, GSK-3b and b-catenin are localized to ATII cells in human lung and there is increased phosphorylation of LRP6 and GSK-3b, which are indicative of WNT signalling pathway activation [Konigshoff and Eickelberg, 2010; Konigshoff et al. 2008] . Canonical WNT pathway activation is enhanced in ATII cells isolated from the lungs of mice following bleomycininduced lung fibrosis, furthermore, WISP1 is upregulated in the ATII cells from patients with IPF and inhibiting WISP1 with neutralizing antibodies ameliorated the bleomycin-induced fibrosis ]. How WNT signalling promotes fibrogenesis is unclear but evidence would suggest that both canonical and noncanonical pathways promotes fibroblast matrix deposition through protection of fibrotic fibroblasts from apoptosis [Chang et al. 2010; Vuga et al. 2009 ] and through the development of EMT Pozharskaya et al. 2009 ].
WNT signalling and TGF-crosstalk TGF-b has been described to activate b-catenin in a number of cell types via GSK-3b in a Smad2/ 3-dependent manner [Caraci et al. 2008; Clifford et al. 2008; Guo et al. 2008; Jian et al. 2006 ]. Furthermore, TGF-b stimulation of epithelial cells leads to an increase in a number of WNT signalling genes [Malizia et al. 2009 ]. It appears that TGF-b can induce WNT signalling directly through the TGF-b type 1 receptor [Jian et al. 2006 ], or indirectly through increased synthesis of SPARC [Chang et al. 2010] . Recently it has been shown that WNT and TGF-b1 pathways are important in the development of pulmonary fibrosis through the effect of a3b1 integrins. This integrin facilitates the binding of b-catenin to Smad2, promoting EMT and the development of lung fibrosis [Kim et al. 2009 ]. Thus, it is possible that disruption of WNT signalling following initial activation of epithelial cell integrin mediated TGF-b activation pathways may lead to the propagation of fibrosis, at the expense of normal repair.
Molecular pathology of IPF
In any complex disease it is likely that there is a complex relationship between the host genes and the environment that leads to the development of disease. This is especially true of diseases associated with aging such as IPF. The genetic changes that predispose to the development of disease may be hereditary, or acquired, or a combination of both. Furthermore, control of gene expression also has a big role to play in determining protein synthesis that ultimately determines the development of disease. Having considered some of the key pathways that may lead to the development of fibrosis it is also important to review some of the molecular processes that may predispose to disruption of repair pathways.
Genetic predisposition to IPF
There is much circumstantial evidence to suggest that genetic factors predispose to IPF. There are variable responses to inhaled fibrogenic dusts, and variable fibrogenic responses in inbred strains of mice. There are a number of genetic diseases including Niemann-Pick, Gaicher disease, Hermansky-Pudlak syndrome, familial hypocalcuric hypercalcaemia and tuberous sclerosis that are associated with lung fibrosis [Lawson and Lloyd, 2006 ]. However, the most compelling evidence is from the familial clustering of some cases of IPF, known as familial pulmonary fibrosis (FPF). Estimates suggest that up to 4% of IPF is familial, and it would appear to be inherited as an autosomal dominant trait, although vertical penetrance is reduced. There are a number of genes that have been associated with IPF [Lawson and Lloyd, 2006] but two are worthy of mention. The first gene to be associated with pulmonary fibrosis was SpC, when multiple mutations in the SFTPC gene was associated with infantile pulmonary fibrosis [Tredano et al. 2004; Nogee et al. 2001] , subsequently other mutations have been found in association with adult IPF and FPF [Lawson et al. 2004; Thomas et al. 2002] . Although it is possible that these genetic mutations lead to fibrosis due to lower levels of surfactant protein C, it is felt more likely that the mutations provoke an unfolded protein response in the ATII cells leading to direct epithelial injury [Beers and Mulugeta, 2005; Whitsett and Weaver, 2002] . More recently mutations in the TERT gene have been identified in patients with FPF [Armanios et al. 2007; Tsakiri et al. 2007 ] and subsequently in sporadic IPF [Diaz de Leon et al. 2010; Mushiroda et al. 2008] . The TERT gene encodes the catalytic component of the telomerase enzyme which is a DNA polymerase adding telomere repeats to the end of chromosomes, which partly offsets the telomere shortening that occurs in DNA replication. Telomeres shorten with each cell division and this ultimately leads to cell death or cell-cycle arrest, thus limiting the capacity of tissue to regenerate. Telomere shortening is thought to be critical in age related disease [Armanios, 2009] . Shortened telomeres have been associated with IPF [Alder et al. 2008] and it has been suggested that telomere shortening in ATII cells promotes the apoptosis that prevents epithelial repair in IPF [Waisberg et al. 2010] .
Epigenetic regulation
The active acquisitions of epigenetic changes are poorly understood but important processes in development, differentiation and disease processes. Chromatin is more than an architectural static carrier of the genetic information encoded in DNA, as it actively mediates dynamic changes in gene function and expression [Fischle et al. 2003 ]. When cells are stimulated with extracellular mediators, histones in the chromatin undergo an array of posttranscriptional modifications on their N-terminal tail domains including acetylation, phosphorylation, sumoylation, ubiquination and methylation. These histone modifications are linked to gene transcription and to the passage of epigenetic information from one cell generation to the next. Acetylation of the core histones by transcriptional coactivators with intrinsic histone acetyltransferase activity result in changes in chromatin configuration, recruitment of cotranscriptional proteins and polymerase II that initiate transcription. In contrast, deacetylation of the core histones is generally associated with transcriptional repression [Sterner and Berger, 2000] . Diverse cellular functions including the regulation of inflammatory mediators, DNA repair and cell proliferation are regulated by changes in the acetylation status of histones.
Under normal physiological conditions, chromatin acetylation is regulated by the balance between histone acetyltransferases (HATs) and deacetylases (HDACs), which is essential for the maintenance of normal cellular functions. Many diseases have been associated with altered patterns of histone acetylation, as a shift in this balance has dramatic consequences on gene transcription and cellular phenotype [Urnov and Wolffe, 2001] .
Histone acetyltransferases and deacetylases
Several transcription coactivators, including p300/CBP (CREB binding protein), PCAF (P300/CBP-associated factor) and GCN5 (General Control Nonderepressible 5), have been found to possess intrinsic HAT activity [de la Cruz et al. 2005 ]. Most HATs exist as multiple subunit complexes, displaying distinct substrate specificities, with associated subunits regulating the activity of the respective catalytic subunits [Marmorstein and Berger, 2001] . Together with histones, nonhistone proteins, particularly transcription factors, are acetylated which markedly affects their function [Tong et al. 2004; Kim et al. 2001 ].
HDACs play a critical role in reversing the hyperacetylation of core histones. HDACs have been described in four classes according to their structures, expression patterns and catalytic mechanisms. Class I comprising HDAC1, HDAC2, HDAC3 and HDAC8. Class II HDACs include HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10, and a subclass, class IIa which includes HDAC6 and HDAC10 containing two catalytic sites. Class III HDACs (Sirt1, Sirt2, Sirt3, Sirt4, Sirt5, Sirt6 and Sirt7) do not have histones as a primary target. HDAC11 contains a conserved domain in the catalytic region of both Class I and Class II and is grouped into Class IV. HDAC complexes are generally recruited to transcription factors by 'bridging' factors: silencing mediator of retinoid and thyroid receptor (SMRT), Co-RE1 silencing transcription factor (CoREST) [Andrés et al. 1999; Schoenherr and Anderson, 1995] , switch independent 3 (mSin3), nuclear receptor corepressor (NCoR), nucleosome remodelling and decatylase (NuRD). These corepressor complexes regulate gene repression and may provide specificity [Yoon et al. 2005; Vermeulen et al. 2004; Jones and Shi, 2003 ]. HDAC1 and HDAC2 exist together in at least three multiprotein complexes, Sin3, NuRD and CoREST [Ballas et al. 2001; You et al. 2001] , and NCoR exist in core repression complexes with HDAC3.
Epigenetic regulation and pulmonary fibrosis PGE 2 , a major eicosanoid product of lung fibroblasts [Elias, 1988] , has been shown to inhibit lung fibroblast proliferation, reduce collagen levels by inhibition of its mRNA synthesis and decrease fibroblast chemotaxis [Kolodsick et al. 2003; Kohyama et al. 2001] , and is thus an autocrine mediator that controls fibroblast cellular over activation. PGE 2 production is defective in fibroblasts from IPF patients (F-IPF) due to diminished expression of COX-2. Thus the decreased capacity of F-IPF to upregulate COX-2 expression and COX-2-derived PGE 2 synthesis in the presence of increasing levels of profibrotic mediators such as TFG-b1 [Keerthisingam et al. 2001; Broekelmann et al. 1991 ] may result in a loss of the normal inhibitory mechanisms and lead to unopposed fibroblast proliferation and collagen synthesis and contribute to the pathogenesis of IPF [Hodges et al. 2004; Thrall et al. 1979] . COX-2 is an immediate early gene and its expression is subject to multilevel regulation through both transcriptional and posttranscriptional mechanisms. COX-2 expression is critically governed by different transcription factors, including CRE-binding protein (CREB) [Xie et al. 1994] , C/EBP [Gorgoni et al. 2001] , activating protein-1 (AP-1) [Subbaramaiah et al. 2001], and NF-kB [Inoue and Tanabe, 1998] , in a highly cell typespecific and stimulus-specific manner. It is well established that binding of activated transcription factors to specific inducible gene promoter sites is tightly controlled by the chromatin state as a result of histone modifications, particularly the balance between histone acetylation and deacetylation [Adcock et al. 2007; Nie et al. 2003 ]. It has been shown that transcription factor binding to the COX-2 promoter in IPF fibroblasts is reduced compared with that in normal lung fibroblasts, an effect that was dynamically linked to reduced histone H3 and H4 acetylation due to decreased recruitment of HATs and increased recruitment of transcriptional corepressor complexes to the COX-2 promoter [Coward et al. 2009 ]. Furthermore, inhibiting HDACs has been shown to reduce the transformation of Figure 2 . Epigenetic regulation of gene transcription in the fibrotic lung; Activation of gene promoter specific transcription factors by cytokines leads to DNA binding and recruitment of histone acetyltransferase (HATs) such as CREB Binding Protein (CBP/p300) and p300/CBP Associated Protein (PCAF). Once recruited the HATs acetylate histone residues within the nucleosome. This produces a conformational change allowing the DNA to unwind from the histones and the recruitment of the larger complexes, TATA Binding Protein (TBP), TBP associated Factor (TAF) and RNA polymerase II (RNA pol II) to form the Pre Initiation Complex (PIC) which is associated with enhanced gene transcription of antifibrotic factors which regulate the repair and angiogenesis following lung damage. The histone deacetylase (HDAC) containing repression complexes CoREST, Sin3a and NCOR when recruited to gene-specific promoter regions repress gene transcription by preventing transcription factor binding and acetylation of histones. When this occurs during lung injury, disordered repair to genes that regulate antifibrotic factors may result in an unopposed profibrotic environment.
normal lung fibroblasts into myofibroblasts [Guo et al. 2009 ] further supporting the concept that epigenetic regulation of the myofibroblast may be deranged in IPF (see Figure 2 ).
Conclusions
Idiopathic pulmonary fibrosis is a progressive and fatal disease resulting from the deposition of disordered extracellular matrix within the pulmonary parenchyma. Although the aetiological, or injurious, agent that triggers IPF is unknown, the origins of fibrogenesis stem from disordered repair following epithelial injury. Indeed it appears that numerous insults may promote fibrosis in the appropriate setting. The initiating events appear to be injuries that promote TGF-b activation by epithelial cells and fibroblasts. However, this may be necessary for the generation of fibrosis but it is unlikely to be sufficient. Certainly much evidence suggests that selfamplifying feed forward loops through disordered signal regulation need to occur on top of the initial injury to promote fibrosis. This can occur through epithelial cell dysfunction with enhanced integrin expression and activation, augmented epithelialmesenchymal interactions through destroyed basement membrane function or EMT. An alternative possibility is that dysregulated fibroblast/myofibroblast responses to epithelial injury drive fibrogenesis. Dysregulated WNT signalling and PGE2 biosynthesis may both promote fibroblast transdifferentiation to myofibroblasts and inhibit fibroblast apoptosis promoting matrix deposition. It is apparent that fibrotic mesenchymal cells have an altered phenotype compared with non-fibrotic mesenchymal cells suggesting genetic or epigenetic changes, which promote disease at the expense of normal wound repair. This wide variety of molecular abnormalities, coupled with the poor prognosis of this disease and the increased risk of malignancy has lead to the emerging concept that IPF is a 'clinically malignant disorder of the lung' [Vancheri et al. 2010] . Recognizing the pathways that result from epithelial injury and identifying the molecular checkpoints that prevent normal healing and promote fibrogenesis are crucial if novel treatments that offer the hope of improved survival in IPF are to be developed. Eitzman, D.T., McCoy, R.D., Zheng, X., Fay, W.P., Shen, T., Ginsburg, D. et al. (1996) Bleomycininduced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97: 232237. Elias, J.A. (1988) Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin-dependent and -independent mechanisms. Am Rev Respir Dis 138: 652658. Emura, M., Nagai, S., Takeuchi, M., Kitaichi, M. and Izumi, T. (1990) In vitro production of B cell growth factor and B cell differentiation factor by peripheral blood mononuclear cells and bronchoalveolar lavage T lymphocytes from patients with idiopathic pulmonary fibrosis. Clin Exp Immunol 82: 133139. Guo, W., Flanagan, J., Jasuja, R., Kirkland, J., Jiang, L. and Bhasin, S. (2008) The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between SMAD3 and WNT/beta-catenin signaling pathways. J Biol Chem 283: 91369145. Imokawa, S., Sato, A., Hayakawa, H., Kotani, M., Urano, T. and Takada, A. (1997) 
